RxDoctor Payments DataLook up a doctor →

Umaprasanna Karnam, MD

Gastroenterology · Riverton, UTNPI 1689623852

Payments from drug & device makers

$420,012in general payments, 2019–2025

Across 832 payments — averaging $504.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim International GmbH$166K
  • Janssen Research & Development, LLC$80K
  • Phathom Pharmaceuticals, Inc.$72K
  • Madrigal Pharmaceuticals$20K
  • AbbVie$19K
  • Sanofi US Services Inc.$18K
  • plus $45K from 37 others

What the payments were for

  • Speaking & faculty fees$100,13283%
  • Travel & lodging$6,2325%
  • Food & beverage$13,66011%
  • Education$1590%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$420,012 in reported general payments places this provider in the 90th percentile of 122 gastroenterology providers in Utah.

See all gastroenterology providers in Utah

Medicare billing

Part B allowed, 2024
$121,246
Medicare patients
529
Services billed
875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase11$81,540
ClenpiqSod Picosulf/Mag Ox/Citric Ac86$14,669
Mesalamine19$14,583
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates194$12,963
LinzessLinaclotide11$12,238
MotegrityPrucalopride Succinate15$9,677
Budesonide DrBudesonide34$9,319
Pantoprazole Sodium288$3,612
Esomeprazole Magnesium44$3,121
Sucralfate92$2,506
Omeprazole133$2,300
Ursodiol11$1,886
Dicyclomine Hcl89$1,839
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl95$1,792
CholestyramineCholestyramine (With Sugar)28$1,539

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$97$81,54011 claims
AbbVieLinzess$18,930$12,23811 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$1,076$9,67715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 122 gastroenterology providers in Utah.

Other gastroenterology in Riverton

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →